Citadel Advisors
RLAY icon

Citadel Advisors’s Relay Therapeutics RLAY Stock Holding History

Citadel Advisors’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.86M Buy
473,682
+297,417
+169% +$4.32M ﹤0.01% 3757
2026
Q1 		$1.75M Buy
176,265
+62,122
+54% +$556K ﹤0.01% 6366
2025
Q4 		$966K Buy
+114,143
New +$815K ﹤0.01% 7471
2025
Q2 		– Sell
-337,268
Closed -$1M – 14674
2025
Q1 		$884K Sell
337,268
-349,610
-51% -$1.37M ﹤0.01% 7241
2024
Q4 		$2.83M Sell
686,878
-2,222,493
-76% -$12.1M ﹤0.01% 4934
2024
Q3 		$20.6M Buy
2,909,371
+1,746,035
+150% +$13M ﹤0.01% 2022
2024
Q2 		$7.58M Buy
1,163,336
+926,136
+390% +$6.33M ﹤0.01% 3166
2024
Q1 		$1.97M Sell
237,200
-360,394
-60% -$3.52M ﹤0.01% 5552
2023
Q4 		$6.58M Sell
597,594
-1,085,255
-64% -$9.16M ﹤0.01% 3420
2023
Q3 		$14.2M Buy
1,682,849
+1,374,834
+446% +$14.8M ﹤0.01% 2261
2023
Q2 		$3.87M Buy
308,015
+287,296
+1,387% +$3.57M ﹤0.01% 4037
2023
Q1 		$341K Sell
20,719
-113,641
-85% -$2.04M ﹤0.01% 9113
2022
Q4 		$2.01M Sell
134,360
-118,380
-47% -$2.27M ﹤0.01% 5484
2022
Q3 		$5.65M Buy
252,740
+223,821
+774% +$4.91M ﹤0.01% 3671
2022
Q2 		$484K Sell
28,919
-71,175
-71% -$1.53M ﹤0.01% 8732
2022
Q1 		$3M Sell
100,094
-152,665
-60% -$3.7M ﹤0.01% 5186
2021
Q4 		$7.76M Buy
252,759
+66,512
+36% +$2.1M ﹤0.01% 3509
2021
Q3 		$5.87M Buy
186,247
+58,996
+46% +$1.99M ﹤0.01% 4000
2021
Q2 		$4.66M Buy
127,251
+478
+0.4% +$15.8K ﹤0.01% 4602
2021
Q1 		$4.38M Buy
126,773
+63,776
+101% +$2.77M ﹤0.01% 4560
2020
Q4 		$2.62M Buy
62,997
+8,904
+16% +$403K ﹤0.01% 4807
2020
Q3 		$2.3M Buy
+54,093
New +$2.06M ﹤0.01% 4463

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Citadel Advisors's RLAY Position: Q2 2026 in Review

Citadel Advisors increased its Relay Therapeutics (RLAY) stake by 169% in Q2 2026, buying an estimated $4.32M and bringing the position to 473,682 shares worth $8.86M. The position accounts for ﹤0.01% of the portfolio, ranked #3757.

Citadel Advisors first reported a position in RLAY in Q3 2020 and has held it in 22 quarters since. The position peaked at $20.6M in Q3 2024. 258 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • Citadel Advisors held 473,682 shares of Relay Therapeutics worth $8.86M as of Q2 2026.
  • Citadel Advisors bought 297,417 Relay Therapeutics shares in Q2 2026, an estimated $4.32M.
  • Relay Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #3757 holding.
  • Citadel Advisors first reported a position in Relay Therapeutics in Q3 2020 and has held it in 22 quarters since.
  • Citadel Advisors's Relay Therapeutics position peaked at $20.6M in Q3 2024.
  • 258 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.